Artwork
iconShare
 
Manage episode 484418029 series 2608063
Content provided by American Psychiatric Association. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by American Psychiatric Association or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this episode of PsychNews Special Report, we explore the evolving landscape of clozapine therapy, reaffirming its role as the gold standard for treatment-resistant schizophrenia and examining its unique benefits in reducing suicidality. We examine key insights from the Psychiatric News article by Gemma Espejo, M.D., and Farah Khorassani, Pharm.D., which highlights challenges in clozapine utilization—including blood monitoring requirements and clinician hesitancy—alongside updates to monitoring protocols and side effect management.

The episode also touches on augmentation strategies, the potential of pharmacogenomics, and promising innovations in psychiatric treatment.

Read the full article in Psychiatric News here: https://www.psychiatryonline.org/doi/10.1176/appi.pn.2025.05.5.10

Listen and Subscribe: Find this episode and more on the APA Medical Mind Podcast Channel or wherever you get your podcasts.

PsychNews Special Report” is a production of Psychiatric News, a media platform dedicated to serving as the primary and most trusted source of information for APA members, other psychiatrists and physicians, health professionals, and the public about developments in the field of psychiatry and mental health that impact clinical care and professional practice. Learn more at psychiatryonline.org/journal/pn.

  continue reading

64 episodes